Vaderis Therapeutics
PrivateLast Round
Series B
Aug 11, 2026
Total Funding Raised
$170.6M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vaderis Therapeutics operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Series B round in August 2026.
Vaderis Therapeutics is a biotechnology company that develops targeted therapies for rare vascular diseases, with a primary focus on hereditary hemorrhagic telangiectasia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaderis Therapeutics Comparables
Compare Vaderis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terremoto Biosciences | 86% | |
| Diagonal Therapeutics | 85% | |
| Kaken Pharmaceutical Co. Ltd | 78% |
For institutional investors. Book with your work email.
Vaderis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 11, 2026 | ||||
| Series A | May 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vaderis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TCG Crossover | Series B |
| Omega Funds | Series B |
| EQT Life Sciences | Series B |
| Perceptive Advisors | Series B |
| Life Sciences at Goldman Sachs Alternatives | Series B |
| Droia Ventures | Series B, Series A |
| Kalehua Capital Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 19, 2026
Grew 16% QoQ, from 19 to 22 employees.
- Aug 11, 2026
$152M round led by TCG Crossover and Goldman Sachs.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 11, 2026
On Aug 12th '26 in Sweden, Vaderis receives $17.5M from EQT Life Sciences as part of its $152M Series B financing, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, to support the global Phase 3 HEROIC study of engasertib.
- receives_financingAug 11, 2026
On Aug 11th '26, Vaderis received an oversubscribed $152M Series B financing in Switzerland, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi, and Droia, to fund operations through regulatory submissions and potential U.S. approval of engasertib.
For institutional investors. Book with your work email.
Vaderis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vaderis Therapeutics's valuation, stock price, and market status.
Is Vaderis Therapeutics a public or private company?
Vaderis Therapeutics is a private company.
What is the current stock price of Vaderis Therapeutics?
Vaderis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vaderis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vaderis Therapeutics worth (valuation)?
Valuation information for Vaderis Therapeutics is not publicly available.
Can I buy Vaderis Therapeutics stock?
Vaderis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vaderis Therapeutics's last funding round?
Vaderis Therapeutics's most recent funding round was Series B on August 11, 2026.
Who are the main investors in Vaderis Therapeutics?
Key investors in Vaderis Therapeutics include TCG Crossover, Life Sciences at Goldman Sachs Alternatives, Medicxi.
Will Vaderis Therapeutics IPO soon?
No public IPO plans have been announced for Vaderis Therapeutics.
How can I track Vaderis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vaderis Therapeutics's shares on secondary markets.